{"name":"RDD Pharma Ltd","slug":"rdd-pharma-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Oxymetazoline gel","genericName":"Oxymetazoline gel","slug":"oxymetazoline-gel","indication":"Nasal congestion (topical gel)","status":"marketed"},{"name":"Phenyephrine","genericName":"Phenyephrine","slug":"phenyephrine","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Oxymetazoline gel","genericName":"Oxymetazoline gel","slug":"oxymetazoline-gel","phase":"marketed","mechanism":"Oxymetazoline is a selective alpha-2 adrenergic receptor agonist that causes vasoconstriction of blood vessels in the nasal mucosa and skin.","indications":["Nasal congestion (topical gel)","Facial erythema / rosacea (topical gel)"],"catalyst":""},{"name":"Phenyephrine","genericName":"Phenyephrine","slug":"phenyephrine","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQNTZfSVM4bUtjdHdaQkdwSkRYRzlZTmtxeU1ZUGQ0cjBfRXd6SlZpSFdHbUFWRUlWUnNEVzh3MGNWYzVoTkR4dVhJWVFXMnJUS1I4c295Wm9fbHZqOEQtRTFIYXk4bjkzQVVyeWFHV0s3MkdiR2NVZlAzT0lyTHV3U2hxbC10SVJVTjVLMEtfb2o3YnBDMVhjMW1UcndBUTZN?oc=5","date":"2026-04-06","type":"pipeline","source":"openPR.com","summary":"Anal Fissure Treatment Market Set to Boom Rapidly by 2033 |Abvie, Novartis AG, Teva Pharmaceuticals, Troikaa - openPR.com","headline":"Anal Fissure Treatment Market Set to Boom Rapidly by 2033 |Abvie, Novartis AG, Teva Pharmaceuticals, Troikaa","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE0wZjdnSzhnVTl4UWxscTZaX3paZGM2SFpUeFhaeWpCWmtZVjhWUEtlUmcxNGhGaGs4bVJQSUFTV19saGlXUVV2WHF0MW5ZMW4tNXotZEI4THZfZkloTjM0?oc=5","date":"2026-01-20","type":"regulatory","source":"Nature","summary":"2025 FDA approvals: volume maintained, but value remains below average - Nature","headline":"2025 FDA approvals: volume maintained, but value remains below average","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE1Va3JBYzBRazBkaHlaYk5tZmNING4wVzYtV0g4UktURmhlNXBCelNpNkRhbTRQWkkydXZJSUJ2X2Y2WUYwUndGeXVJWEYyV3dxcW9wLXVyUzRfcmNuTmhGbVI0cDBkb2w3M1h2OXRPTmk?oc=5","date":"2024-12-23","type":"pipeline","source":"Built In","summary":"20 Pharmaceutical Companies in Israel to Know - Built In","headline":"20 Pharmaceutical Companies in Israel to Know","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOVnlCTXpaVDdPYXRaTGV0YXN0V2lySE83QkdRdjFycGEtaFNVRWxiRjVaZ25pTXVkaFg2UThoV0V5NXhDbkVzUldGUUktS2ZqbzJrelg3NUV3VnN3TVNMTTRadW9oSG5fT21mMEhfR1E4a3QzeXlTdThiSUk5bkh5eXZMVmFyWDJQdExDYTFvSWdCY0RGdzhOaXlJVU5MSUU?oc=5","date":"2023-05-30","type":"pipeline","source":"The Business Journals","summary":"Temperato resigns as CEO of Raleigh drugmaker - The Business Journals","headline":"Temperato resigns as CEO of Raleigh drugmaker","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQWmN2QktZM0V5dGNwbVhkU2hSRDdKaGd3M2tnNFhfbGtld2xLOU45cHdOdmpfYXFqN2piRFhhTUtDTndKNC15VS1raFJRSENDdTA5anJoOVNrUFptMHU2NmgycGhJcTdUMDd5ekhpNzRLTmx3NXU5aEFPR1lRMUM3ci1tNi15ZjBaSlVqeHZkYmwwcVZScERMTExSWWNpUl9DR2pIMjVRcklvbnY2bmlxellielpPYU5VeVk4TjBUbXhBbm8?oc=5","date":"2022-07-19","type":"pipeline","source":"European Pharmaceutical Review","summary":"Transpire Bio signs with Recipharm for inhaled medicine development - European Pharmaceutical Review","headline":"Transpire Bio signs with Recipharm for inhaled medicine development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOdHkxQTdkTlpEZDRpaFlHZmFDN212RmFUNXFRSXBLNlU4b0M3UXM2LTQta2dhVWRubmktZUFFNlVESDRGU3Q2SVliNU9wcDRpaExpY1JNWDhNRUk0YUMyX2xER0xVTjVOT2RsZWZEck1kR25POW1Ielp4WFhFVDhWNG5TWWVaN255Q0d0clFHT3pGSDhhS0pzNFpTU1VHTndLclZnSDU5aUhVTGlKdXc?oc=5","date":"2022-01-03","type":"pipeline","source":"O'Dwyer PR","summary":"PR News | On the Move: Autumn Communications Hires Strasburg as SVP - Mon., Jan. 3, 2022 - O'Dwyer PR","headline":"PR News | On the Move: Autumn Communications Hires Strasburg as SVP - Mon., Jan. 3, 2022 - O'Dwyer PR","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAJBVV95cUxQSlU0dXVQeGxRYm5TemFNbUltQlR0Tl9xNU1WblZST2ZnMUVYVndIazdfMWYwck9WdVh3eFUyQUxnMjFHN3FGN3U2T2ZCSURmeHZOdnVpQm55ZjY4QmpUbjNiVVFZbGRZUWVCYWFpMHNNRjdxd1RGSW1NWGdialJtM2t1UHVaR2ozY1ZQS1ZnVnFRclphR3EwNzl3UDRqU3g3N3g2enNJdEVYaTdtbE5HRGhEeW5lM0RSNndOZmVRSTl4QWpwdm1fZlUyal9YTW5GSnVNYlRsdVFaNkQ5ZjBqckVKQ2VtQlNwS1FGMkJjb3pwVHZDdTNmaW1Oal8wakRIbWxwdEFiM28xZ2czUHhKTWhBZnIwLUR5aFVITA?oc=5","date":"2019-11-13","type":"deal","source":"PR Newswire","summary":"RDD Pharma Enters into Non-Binding Letter of Intent to Acquire Naia Rare Diseases, Strengthening Gastroenterology Orphan Disease Pipeline - PR Newswire","headline":"RDD Pharma Enters into Non-Binding Letter of Intent to Acquire Naia Rare Diseases, Strengthening Gastroenterology Orphan","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":1,"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}